Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) will participate in the 2026 BIO International Convention, held June 22-25, 2026, in San Diego, California.
The company highlights recent positive preclinical phototoxicity results and the start of IND-enabling GLP genotoxicity studies for EB-003, which are expected to support an eventual IND submission and potential Phase 1 clinical entry. Enveric’s management will host meetings with potential strategic partners, and registered attendees can request meetings via the BIO One-on-One Partnering platform.
Enveric Biosciences (NASDAQ: ENVB) will participate in the UBS 3rd Virtual CNS Day on June 15, 2026. Company management plans one-on-one meetings with registered investors to discuss its business and clinical development strategy, recent corporate achievements, and anticipated milestones in psychiatric and neurological therapeutics.
Enveric Biosciences (NASDAQ: ENVB) has initiated IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003, a small-molecule therapeutic for psychiatric and neurological disorders.
The GLP studies, following ICH S2(R1) guidelines, include Ames and Micronucleus assays and support a potential future Phase 1 first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) reported positive preclinical in vitro phototoxicity results for lead neuroplastogen EB-003. Testing showed no photoreactive potential, reducing safety concerns for chronic treatment of neuropsychiatric disorders, including depression, anxiety and PTSD. This marks a further preclinical safety milestone as Enveric prepares for first-in-human Phase 1 trials.
Enveric Biosciences (NASDAQ: ENVB) reported first quarter 2026 results and a corporate update. Net loss attributable to stockholders was $1.6 million (loss/share $1.08) versus $2.2 million (loss/share $14.58) a year earlier, with $4.9 million cash at March 31, 2026.
The company advanced lead candidate EB-003 through IND-enabling studies and reported preclinical data showing dual Gq and β-arrestin 5-HT2A signaling and reduced conditioned fear in a PTSD model. Enveric strengthened its IP portfolio, noted withdrawal of a Post-Grant Review petition relating to patents tied to bretisilocin (GM-2505), and enhanced EVM301 coverage.
Enveric raised $2.8 million in Q1 offerings, followed by a private placement of up to $13.9 million (including $5 million upfront) and $1.5 million from warrant exercises, bringing cash to about $10.3 million as of May 15, 2026, which it believes funds operations into Q1 FY 2027.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of US Patent No. 12,605,361 for methods of treating psychiatric disorders using its EVM301 Series carboxylated psilocybin derivatives. The April 21, 2026 patent broadens protection for tryptamine-based drug candidates and supports development of lead candidate EB003 targeting depression and anxiety.
Enveric Biosciences (NASDAQ: ENVB) highlighted preclinical results for EB-003, a dual 5-HT2A/5-HT1B modulator. A single dose significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05), indicating a rapid reduction in conditioned fear in a validated PTSD model.
The company positioned EB-003 as a next-generation neuroplastogen targeting neuroplasticity and mood signaling pathways as interest in psychedelic-inspired therapies grows.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) said CEO Joseph Tucker, Ph.D., will join a panel at Needham’s Virtual Psychedelics Forum on Monday, April 27, 1:00 PM - 2:00 PM ET.
The panel topic is "Beyond TRD: Non-Hallucinogens and New Indications". Management will hold one-on-one investor and partner meetings to review clinical strategy and anticipated milestones. Registration is available online.
Enveric Biosciences (NASDAQ: ENVB) closed a private placement priced at-the-market on April 17, 2026, raising approximately $5.0 million in gross proceeds from the sale of 2,222,223 shares (or pre-funded warrants) and accompanying warrants at $2.25 per share.
The offering includes Series I warrants and short-term Series J warrants to buy up to 2,222,223 shares each at a $2.00 exercise price, potentially providing an additional $8.9 million if fully exercised; the company intends to use net proceeds for product development, working capital and general corporate purposes.